伊匹木单抗-话题@MedSci

#伊匹木单抗#

23篇内容 | 2405人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2036798, encodeId=4b1b2036e9885, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=CheckMate-743 III期研究结果：一线治疗不可切除的恶性胸膜间皮瘤，纳武利尤单抗联合伊匹木单抗显示出持久获益, objectType=article, longId=217090, objectId=179321e09027, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=179321e09027, replyNumber=0, likeNumber=169, createdTime=2021-10-25, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=179321e09027, moduleTitle=CheckMate-743 III期研究结果：一线治疗不可切除的恶性胸膜间皮瘤，纳武利尤单抗联合伊匹木单抗显示出持久获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=179321e09027)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036800, encodeId=355d203680026, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=Nat Commun：伊匹木单抗和尼沃鲁米单抗治疗脑膜癌：II期研究 , objectType=article, longId=218533, objectId=2cb92185334f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cb92185334f, replyNumber=0, likeNumber=189, createdTime=2022-02-28, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cb92185334f, moduleTitle=Nat Commun：伊匹木单抗和尼沃鲁米单抗治疗脑膜癌：II期研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cb92185334f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036797, encodeId=79322036e9753, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=JAMA Oncol：纳武利尤单抗（Nivolumab）联合伊匹木单抗（Ipilimumab）对比纳武利尤单抗治疗既往治疗过的IV期鳞状非小细胞肺癌的疗效：3期临床研究Lung-MAPS1400I, objectType=article, longId=214350, objectId=f3df214350a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3df214350a4, replyNumber=0, likeNumber=184, createdTime=2022-05-30, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3df214350a4, moduleTitle=JAMA Oncol：纳武利尤单抗（Nivolumab）联合伊匹木单抗（Ipilimumab）对比纳武利尤单抗治疗既往治疗过的IV期鳞状非小细胞肺癌的疗效：3期临床研究Lung-MAPS1400I, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3df214350a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036796, encodeId=b7462036e96b4, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=欧狄沃（纳武利尤单抗）联合化疗及欧狄沃联合伊匹木单抗治疗晚期不可切除或转移性食管鳞癌患者均可带来显著生存获益, objectType=article, longId=209794, objectId=fb68209e9495, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb68209e9495, replyNumber=0, likeNumber=166, createdTime=2021-12-02, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb68209e9495, moduleTitle=欧狄沃（纳武利尤单抗）联合化疗及欧狄沃联合伊匹木单抗治疗晚期不可切除或转移性食管鳞癌患者均可带来显著生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb68209e9495)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036794, encodeId=b0f52036e942b, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=美国FDA批准欧狄沃®（纳武利尤单抗）联合伊匹木单抗成为且目前**获批的免疫疗法，用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者, objectType=article, longId=201898, objectId=555f2018985e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=555f2018985e, replyNumber=0, likeNumber=73, createdTime=2020-11-21, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=555f2018985e, moduleTitle=美国FDA批准欧狄沃®（纳武利尤单抗）联合伊匹木单抗成为且目前**获批的免疫疗法，用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=555f2018985e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036792, encodeId=89332036e9275, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=又一适应症获批！欧狄沃®（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于转移或复发性非小细胞肺癌患者一线治疗, objectType=article, longId=194917, objectId=cfd319491ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfd319491ed0, replyNumber=0, likeNumber=104, createdTime=2021-04-26, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfd319491ed0, moduleTitle=又一适应症获批！欧狄沃®（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于转移或复发性非小细胞肺癌患者一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfd319491ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036791, encodeId=95972036e91c6, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=CheckMate -9LA临床试验数据积极！欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗显著提高一线转移性非小细胞肺癌患者总生存, objectType=article, longId=194157, objectId=c3b319415e0d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3b319415e0d, replyNumber=0, likeNumber=74, createdTime=2020-11-25, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3b319415e0d, moduleTitle=CheckMate -9LA临床试验数据积极！欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗显著提高一线转移性非小细胞肺癌患者总生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3b319415e0d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036787, encodeId=0eba2036e874b, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=喜大普奔！纳武利尤单抗联合伊匹木单抗双免疫疗法惠及肝细胞癌患者，客观缓解率达33%, objectType=article, longId=189909, objectId=76111899099c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76111899099c, replyNumber=0, likeNumber=160, createdTime=2020-06-13, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76111899099c, moduleTitle=喜大普奔！纳武利尤单抗联合伊匹木单抗双免疫疗法惠及肝细胞癌患者，客观缓解率达33%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76111899099c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036795, encodeId=e0c82036e95f6, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=美国FDA批准欧狄沃联合伊匹木单抗用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者，成为且目前**获批的免疫疗法, objectType=article, longId=201903, objectId=4d5c201903de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d5c201903de, replyNumber=0, likeNumber=83, createdTime=2021-09-21, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d5c201903de, moduleTitle=美国FDA批准欧狄沃联合伊匹木单抗用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者，成为且目前**获批的免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d5c201903de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036788, encodeId=b5282036e8817, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=百时美施贵宝宣布，美国与欧洲监管机构已接受欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于肺癌一线治疗的申请, objectType=article, longId=191924, objectId=e2a4191924a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2a4191924a2, replyNumber=0, likeNumber=63, createdTime=2021-02-23, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2a4191924a2, moduleTitle=百时美施贵宝宣布，美国与欧洲监管机构已接受欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于肺癌一线治疗的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2a4191924a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036790, encodeId=2d002036e90bc, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=CheckMate-227 三年随访数据证实：欧狄沃（纳武利尤单抗）联合伊匹木单抗为一线转移性非小细胞肺癌患者带来持久且长期的生存获益, objectType=article, longId=194156, objectId=071f1941562d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=071f1941562d, replyNumber=0, likeNumber=57, createdTime=2021-03-07, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=071f1941562d, moduleTitle=CheckMate-227 三年随访数据证实：欧狄沃（纳武利尤单抗）联合伊匹木单抗为一线转移性非小细胞肺癌患者带来持久且长期的生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=071f1941562d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036793, encodeId=c0562036e934f, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=与化疗相比，纳武利尤单抗联合伊匹木单抗用于既往未经治疗的恶性胸膜间皮瘤患者显示出持久的生存获益, objectType=article, longId=199473, objectId=97211994e361, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97211994e361, replyNumber=0, likeNumber=156, createdTime=2020-08-27, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97211994e361, moduleTitle=与化疗相比，纳武利尤单抗联合伊匹木单抗用于既往未经治疗的恶性胸膜间皮瘤患者显示出持久的生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97211994e361)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036789, encodeId=53b12036e8909, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点, objectType=article, longId=192692, objectId=46461926922a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46461926922a, replyNumber=0, likeNumber=167, createdTime=2021-03-21, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46461926922a, moduleTitle=CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46461926922a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036785, encodeId=35a72036e8519, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=BMS公布CheckMate 227临床研究第1部分最终结果：O药联合低剂量伊匹木单抗用于治疗NSCLC患者总生存获益显著优于化疗, objectType=article, longId=180256, objectId=d2b81802562b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2b81802562b, replyNumber=0, likeNumber=69, createdTime=2019-10-26, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2b81802562b, moduleTitle=BMS公布CheckMate 227临床研究第1部分最终结果：O药联合低剂量伊匹木单抗用于治疗NSCLC患者总生存获益显著优于化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2b81802562b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036786, encodeId=40da2036e868c, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益, objectType=article, longId=181894, objectId=a3881818949e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3881818949e, replyNumber=0, likeNumber=136, createdTime=2020-06-19, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3881818949e, moduleTitle=III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3881818949e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036781, encodeId=1a4b2036e81a3, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=喜大普奔|纳武利尤单抗联合低剂量伊匹木单抗一线治疗中高危晚期肾细胞癌获欧盟委员会批准, objectType=article, longId=158125, objectId=cd04158125a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd04158125a7, replyNumber=0, likeNumber=78, createdTime=2019-05-27, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd04158125a7, moduleTitle=喜大普奔|纳武利尤单抗联合低剂量伊匹木单抗一线治疗中高危晚期肾细胞癌获欧盟委员会批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd04158125a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036784, encodeId=01f72036e84b3, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=ASCO肝癌治疗进展：O药联合伊匹木单抗客观缓解率31%, objectType=article, longId=167691, objectId=56da16e69151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56da16e69151, replyNumber=0, likeNumber=149, createdTime=2020-02-23, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56da16e69151, moduleTitle=ASCO肝癌治疗进展：O药联合伊匹木单抗客观缓解率31%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56da16e69151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036782, encodeId=068e2036e8291, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=纳武利尤单抗联合伊匹木单抗一线治疗肾细胞癌获欧盟委员会批准, objectType=article, longId=158137, objectId=4a7415813e30, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a7415813e30, replyNumber=0, likeNumber=161, createdTime=2019-06-30, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a7415813e30, moduleTitle=纳武利尤单抗联合伊匹木单抗一线治疗肾细胞癌获欧盟委员会批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a7415813e30)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036783, encodeId=65d62036e8360, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a>, objectTitle=2019 ASCO：百时美施贵宝首次发布纳武利尤单抗联合伊匹木单抗治疗晚期肝细胞癌的临床研究结果, objectType=article, longId=167618, objectId=e3fc16e61813, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3fc16e61813, replyNumber=0, likeNumber=160, createdTime=2019-12-23, rootId=0, userName=bsmagic9132, userId=3eaf430, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3fc16e61813, moduleTitle=2019 ASCO：百时美施贵宝首次发布纳武利尤单抗联合伊匹木单抗治疗晚期肝细胞癌的临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3fc16e61813)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

伊匹木单抗

2020-05-29

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

CheckMate-743 III期研究结果：一线治疗不可切除的恶性胸膜间皮瘤，纳武利尤单抗联合伊匹木单抗显示出持久获益

2021-10-25

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

Nat Commun：伊匹木单抗和尼沃鲁米单抗治疗脑膜癌：II期研究

2022-02-28

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

JAMA Oncol：纳武利尤单抗（Nivolumab）联合伊匹木单抗（Ipilimumab）对比纳武利尤单抗治疗既往治疗过的IV期鳞状非小细胞肺癌的疗效：3期临床研究Lung-MAPS1400I

2022-05-30

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

欧狄沃（纳武利尤单抗）联合化疗及欧狄沃联合伊匹木单抗治疗晚期不可切除或转移性食管鳞癌患者均可带来显著生存获益

2021-12-02

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

美国FDA批准欧狄沃®（纳武利尤单抗）联合伊匹木单抗成为且目前**获批的免疫疗法，用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者

2020-11-21

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

又一适应症获批！欧狄沃®（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于转移或复发性非小细胞肺癌患者一线治疗

2021-04-26

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

CheckMate -9LA临床试验数据积极！欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗显著提高一线转移性非小细胞肺癌患者总生存

2020-11-25

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

喜大普奔！纳武利尤单抗联合伊匹木单抗双免疫疗法惠及肝细胞癌患者，客观缓解率达33%

2020-06-13

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

美国FDA批准欧狄沃联合伊匹木单抗用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者，成为且目前**获批的免疫疗法

2021-09-21

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

百时美施贵宝宣布，美国与欧洲监管机构已接受欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于肺癌一线治疗的申请

2021-02-23

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

CheckMate-227 三年随访数据证实：欧狄沃（纳武利尤单抗）联合伊匹木单抗为一线转移性非小细胞肺癌患者带来持久且长期的生存获益

2021-03-07

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

与化疗相比，纳武利尤单抗联合伊匹木单抗用于既往未经治疗的恶性胸膜间皮瘤患者显示出持久的生存获益

2020-08-27

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点

2021-03-21

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

BMS公布CheckMate 227临床研究第1部分最终结果：O药联合低剂量伊匹木单抗用于治疗NSCLC患者总生存获益显著优于化疗

2019-10-26

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益

2020-06-19

仁者大医 (审核中...)

前往app查看评论内容

#伊匹木单抗#

喜大普奔|纳武利尤单抗联合低剂量伊匹木单抗一线治疗中高危晚期肾细胞癌获欧盟委员会批准

2019-05-27

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

ASCO肝癌治疗进展：O药联合伊匹木单抗客观缓解率31%

2020-02-23

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

纳武利尤单抗联合伊匹木单抗一线治疗肾细胞癌获欧盟委员会批准

2019-06-30

bsmagic9132 (审核中...)

前往app查看评论内容

#伊匹木单抗#

2019 ASCO：百时美施贵宝首次发布纳武利尤单抗联合伊匹木单抗治疗晚期肝细胞癌的临床研究结果

2019-12-23

科室
- - 订阅+
  - 更多科室
工具
服务